| Name | Transforming protein RhoA | ||
| UniProt ID | RHOA_HUMAN | ||
| Gene Name | RHOA | ||
| Gene ID | 387 | ||
| Synonyms |
RHOA, ARH12, ARHA, EDFAOB, RHO12, RHOH12
|
||
| Sequence |
MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYVADIEVDGKQVELALWDT
AGQEDYDRLRPLSYPDTDVILMCFSIDSPDSLENIPEKWTPEVKHFCPNVPIILVGNKKD LRNDEHTRRELAKMKQEPVKPEEGRDMANRIGAFGYMECSAKTKDGVREVFEMATRAALQ ARRGKKKSGCLVL |
||
| Pathway Map | MAP LINK | ||
| T.C. Number | 1.A.17.1.1; 9.A.78.1.1 | ||
| KEGG ID | hsa387 | ||
| TTD ID | T96736 | ||
| Pfam | PF00009; PF00025; PF00071; PF04670; PF08477; PF08776; PF09439 | ||
| Pair Name | Daurinoline, Sorafenib | |||
| Phytochemical | Daurinoline | |||
| Drug | Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Regulate Info | Down-regulation | Transforming protein RhoA | Activity | |
| Result | Our study provides insights into the molecular mechanisms underlying DS-induced inhibition of VM, which may facilitate the development of a novel clinical anti-HCC drug. Moreover, our findings suggest that the combination of DS and sorafenib constitutes a potential therapeutic strategy for HCC. | |||
